Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation by Itonaga Hidehiro et al.
1 
Clinical impact of the loss of chromosome 7q on outcomes of patients with 
myelodysplastic syndromes treated with allogeneic hematopoietic stem cell 
transplantation 
 
Hidehiro Itonaga (1), Ken Ishiyama (2), Kazunari Aoki (3), Jun Aoki (4), Takayuki 
Ishikawa (5), Kazuteru Ohashi (6), Takayuki Fukuda (7), Yukiyasu Ozawa (8), Shuichi 
Ota (9), Naoyuki Uchida (10), Tetsuya Eto (11), Koji Iwato (12), Yuju Ohno (13), Minoko 
Takanashi (14), Tatsuo Ichinohe (15), Yoshiko Atsuta (16)(17), Yasushi Miyazaki (1)(18) 
 
(1) Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan. 
(2) Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan. 
(3) Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
University, Kyoto, Japan. 
(4) Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan. 
(5) Department of Hematology, Kobe City General Hospital, Kobe, Japan. 
(6) Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
Komagome Hospital, Tokyo, Japan. 
(7) Department of Hematopoietic Stem Cell Transplantation, National Cancer Center 
2 
Hospital, Tokyo, Japan. 
(8) Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya Japan. 
(9) Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan. 
(10) Department of Hematology, Federation of National Public Service Personnel Mutual 
Aid Associations Toranomon Hospital, Tokyo, Japan. 
(11) Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan. 
(12) Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb 
Survivors Hospital, Hiroshima, Japan. 
(13) Department of Internal Medicine, Kitakyushu Municipal Medical Center, Fukuoka, 
Japan. 
(14) Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan. 
(15) Department of Hematology and Oncology, Research Institute for Radiation Biology 
and Medicine, Hiroshima University, Hiroshima, Japan. 
(16) Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan. 
(17) Department of Healthcare Administration, Nagoya University Graduate School of 
Medicine, Nagoya, Japan. 
(18) Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, 
Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan. 
3 
 
Key words: myelodysplastic syndrome, allogeneic hematopoietic stem cell 
transplantation, monosomy 7, partial deletion of 7q, der(1;7)(q10;p10) 
 
Running title: Transplantation for MDS with loss of chromosome 7q 
 




Abstract: 199 words 
Supplemental Table: 7 




Hidehiro Itonaga, MD, PhD, 









We conducted a nationwide retrospective study to evaluate the prognostic influence of +1, 
der(1;7)(q10;p10) [hereafter der(1;7)] and -7/del(7q) after allogeneic hematopoietic stem 
cell transplantation (allo-HSCT) for de novo myelodysplastic syndromes (MDS). In this 
database, 69 MDS patients with der(1;7), 75 with -7/del(7q), and 511 with normal 
karyotype (NK) underwent allo-HSCT at advanced disease status. The 3-year overall 
survival (OS) and cumulative incidence of relapse (CIR) were 50.4% and 19.4% for those 
with der(1;7), 36.2% and 38.4% for -7/del(7q), and 51.1% and 20.7% for NK, respectively. 
In the multivariate analysis, the presence of -7/del(7q) correlated with a significantly 
shorter OS (HR [95%CI], 1.38 [1.00-1.89]; P=.048) and higher CIR (HR, 2.11 [1.36-
3.28]; P=.001) than those with NK. There were 23 patients with der(1;7), 29 with -
7/del(7q), and 347 with NK who underwent allo-HSCT at early disease status. The 3-year 
OS and CIR were as follows: 47.3% and 9.5% for the der(1;7) group, 70.5% and 13.8% 
for -7/del(7q), and 70.9% and 5.6% for NK, respectively. No significant differences were 
observed in OS and CIR among three groups. The impact of the loss of chromosome 7q 




 Myelodysplastic syndromes (MDS) are clonal hematopoietic stem-cell disorders which 
are characterized by ineffective hematopoiesis with one or more lineages of cytopenias 
[1]. Acquired cytogenetic abnormalities at the time of diagnosis are one of the major and 
independent prognostic factors in outcome predictions for MDS. In the International 
Prognostic Scoring System (IPSS) [2], abnormalities on chromosome 7 have been 
categorized as a poor-risk karyotype, which comprises various patterns including 
monosomy 7, the partial deletion of 7q [del(7q)], and unbalanced translocations 
der(1;7)(q10;p10). In the revised IPSS [3], abnormalities on chromosome 7 have been 
subdivided into 3 groups (i.e. monosomy 7, del(7q), or any others), suggesting that the 
impact of the loss of 7q on the prognosis of MDS may differ depending on its pattern. 
 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially 
curative therapeutic option for MDS patients, but is associated with severe toxicity [4-6]; 
therefore, estimations of the outcomes of patients after allo-HSCT are crucial for 
establishing therapeutic strategies. Among several prognostic scoring systems, 
cytogenetic abnormalities are the most significant indicator of post-transplant outcomes 
[7-10]. 
The International System for Human Cytogenetic Nomenclature (2005) described that 
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46,XY (or 46,XX), +1, der(1;7)(q10;p10) [hereafter der(1;7)] was characterized by an 
allelic imbalance in trisomy 1q and monosomy 7q [11]. Thus, der(1;7) is currently 
considered to be a “karyotypic variant” of monosomy 7 or del(7q) [hereafter -7/del(7q)]. 
Previous studies showed that patients with der(1;7) had different clinical and pathological 
features from those with -7/de(7q) [12-14]. However, due to the small number of patients 
who received allo-HSCT in these studies, the prognostic impact of the different types of 
the loss of 7q on post-transplant outcomes was not fully evaluated. 
In order to more clearly estimate the post-transplant outcomes of MDS with the loss of 
7q, we performed a retrospective analysis on patients with der(1;7) or -7/del(7q) who 
were treated with allo-HSCT using the Transplant Registry Unified Management Program 
(TRUMP) database. 
 
Patients and methods 
Date collection 
Data on adult patients (aged 16 years or older) with de novo MDS who underwent their 
first allo-HSCT between January 1, 1999, and December 31, 2012, were collected by the 
Japan Society for Hematopoietic Cell Transplantation (JSHCT) and the Japanese Data 
Center for Hematopoietic Cell Transplantation (JDCHCT) using TRUMP [15-17]. Data 
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on these patients were collected and updated as of December 31, 2013. This study was 
approved by the TRUMP Committee (approval no. 8-7), and by the Ethics Committee of 
Nagasaki University Hospital (approval no. 12052896) at which this study was organized. 
 
Patient selection 
The original dataset consisted of 4,577 adults who were diagnosed with MDS according 
to the French–American–British (FAB) classification [18]. The patients included in the 
present study had a cytogenetic report at diagnosis which identified der(1;7) or -7/del(7q) 
as the sole clonal cytogenetic abnormality (at least two cells with an identical 
rearrangement). Patients with chronic myelomonocytic leukemia or secondary- and 
therapy-related MDS were excluded from this study. Data on 1,054 patients with MDS 
were collected from this dataset: 92 and 104 patients with der(1;7) and -7/del(7q) as the 
sole cytogenetic abnormality, respectively; 858 patients with normal karyotype, who were 
included in this study as a reference group. 
 
Study end-points and definitions 
 The primary outcome studied was survival. Patients were considered to have an event at 
the time of death from any cause; survivors were censored at the last follow-up. Relapse 
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was defined as disease recurrence, and transplantation-related mortality (TRM) was 
considered to be a competing event in the present study. TRM was defined as death 
without evidence of disease recurrence after allo-HSCT. 
The following karyotypic descriptions were regarded as der(1;7)(q10;p10), as 
previously reported [12]: der(1;7)(q10;p10); der(1)t(1;7)(p11;p11); +t(1;7)(p11;p11),-7; 
der(1;7)(p10;q10); and dic(1;7)(p11;q11). 
Data collected for the analysis included clinical characteristics, such as age at allo-HSCT, 
gender, disease subtype according the FAB classification at diagnosis [18], IPSS at 
diagnosis, bone marrow blast percent at transplantation, the year of allo-HSCT, time from 
MDS diagnosis to transplantation, performance status (PS) according to the Eastern 
Cooperative Oncology Group criteria at transplantation, type of donor source, ABO 
matching between the recipient and donor, date alive at the last follow-up, and date and 
cause of death. Conditioning regimens were classified as myeloablative, reduced-
intensity, and non-myeloablative conditioning according to established criteria [19, 20]. 
GVHD prophylaxis was a cyclosporine- or tacrolimus-based regimen. HLA-A, -B, and -
DRB1 were identified by serological or molecular typing in related donors using 
molecular typing in unrelated bone marrow donors and serological typing in unrelated 
cord blood donors [21, 22]. To reflect current practices in Japan, the number of HLA 
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mismatches was assessed with respect to serological data in related and unrelated cord 
blood donors, and by allele data in unrelated bone marrow donors. Due to missing data 
on IPSS components at allo-HSCT in TRUMP, the disease risk was stratified according 
to the FAB classification as previously reported [23, 24]; early disease status contained 
those who had stayed refractory anemia (RA) or RA with ring sideroblasts (RARS) until 
allo-HSCT. Patients who were diagnosed as RA with excess blasts (RAEB) or RAEB in 




Continuous variables were compared using the Wilcoxon rank-sum test or Kruskal-
Wallis test. Categorical variables were compared between groups using the chi-squared 
test. The probabilities of OS were estimated by the Kaplan-Meier method and group 
comparisons were performed by the log-rank test. Cumulative incidence of relapse (CIR) 
and TRM were estimated in a competing risk setting, and group comparisons were 
performed by the Gray test. Regarding relapse, death before relapse was the competing 
event; and for TRM, death after relapse was the competing event [25, 26]. In order to 
assess variables potentially affecting post-transplant outcomes, OS was evaluated using 
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Cox’s proportional hazards regression models, whereas the probabilities of relapse and 
TRM were evaluated using the Fine and Gray proportional hazards model for the 
subdistribution of competing risks [26]. 
 Factors associated with at least borderline significance (P ≤.10) in the univariate analysis 
and cytogenetic groups were subjected to a multivariate analysis using a backward 
stepwise covariate selection. Potential interactions between covariates were also 
examined. Effect estimates were expressed as hazard ratios (HRs) with 95% confidence 
intervals (CIs). All P-values were 2-tailed, and P-values ≤.05 were considered to be 
significant. All statistical analyses were performed using Stata software, version 12 (Stata, 
College Station, Tx, USA.), and graphical presentations were performed using EZR 




In our entire cohort, der(1;7) group was likely to be older than -7/del(7q) and normal 
karyotype groups (P<.001); median age were 55.5 years (range, 18-70 years) in der(1;7) 
group; 52.5 years (range, 16-73 years) in -7/del(7q) group; 50.0 years (range, 16-73 years) 
in normal karyotype group. Male predominance was noted in both der(1;7) and -7/del(7q) 
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groups: male were 78 out of 94 (84.8%) in der(1;7) group; 72 out of 104 (69.2%) in -
7/del(7q) group; 519 out of 858 (60.5%) in normal karyotype group. This tendency was 
also evident in der(1;7) group compared to -7/del(7q) group (P=.012). 
As demonstrated in previous studies, MDS patients with der(1;7) were more likely to 
show a lower percentage of myeloblasts and slower disease progression than those with -
7/del(7q) [12, 13]. In order to estimate the prognostic value of der(1;7) and -7/del(7q) in 
detail, we analyzed post-transplant outcomes by the disease status, and patients were 
divided into two groups; 655 (62.1%) at advanced status, and 399 (37.9%) at early disease 
status at transplantation. The demographic and baseline characteristics of patients are 
shown in Table 1. 
 
Transplantation outcomes by disease-risk stratification 
In the entire cohort, the 3-year probability of OS after allo-HSCT was 57.2% (95% CI 
53.9-60.3); the 3-year CIR and TRM were 16.3% (95% CI 14.0-18.7%) and 27.0% (95% 
CI 24.3-29.9%), respectively. The univariate analysis demonstrated that patients with 
advanced disease status showed a worse OS (P<.001) and increased CIR (P<.001) than 
those with early disease status (Supplemental Figure 1A, B). However, no significant 
difference was observed in TRM by the disease status (Supplemental Figure 1C). Among 
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the patients with both advanced and early disease status, no significant difference was not 
observed for the cumulative incidences of neutrophil engraftment, acute-, and chronic-
GVHD by each cytogenetic group (data not shown). 
 
OS by the cytogenetic group in patients with advanced disease status 
 Among those with advanced disease status at allo-HSCT, 69, 75, and 511 patients had 
der(1;7), -7/del(7q), and normal karyotype, respectively (Supplemental Table 1). 
 The 3-year probabilities of OS after allo-HSCT were 50.4% (95% CI 37.4-62.0%), 
36.2% (95% CI 24.7-47.8%), and 51.1% (95% CI 46.4-55.7%) in der(1;7), -7/del(7q), 
and normal karyotype groups, respectively (Figure 1A). In the univariate analysis using 
the log-rank test, OS was significantly shorter in -7/del(7q) group than in normal 
karyotype group (P=.011), whereas no significant difference was noted in OS between 
der(1;7) and normal karyotype groups (P=.780). In the multivariate analysis, -7/del(7q) 
group was a significantly worse factor than normal karyotype group (HR 1.38, 95% CI 
1.00-1.89, P=.048), while der(1;7) group was not (HR 0.90, 95% CI 0.62-1.31, P=.583) 
(Table 2). There was no interaction modification between the cytogenetic group and other 
covariates. Four factors other than the cytogenetic group correlated with worse OS: 
recipient age (≥60 years, HR 1.39, 95% CI 1.05-1.85, P=.023), PS at transplantation (PS 
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1-4, HR 1.56, 95% CI 1.22-1.99, P<.001; missing data on PS, HR 1.87, 95% CI 1.26-
2.77, P=.002), the type of donor source (unrelated cord blood, HR 1.85, 95% CI 1.33-
2.56, P<.001), and the interval from diagnosis to transplantation (>7.8 months, HR 1.54, 
95% CI 1.22-1.95, P<.001) (Supplemental Table 2). 
 
CIR and TRM by the cytogenetic group in patients with advanced disease status 
 The 3-year CIR were 19.4% (95% CI 10.5-30.3%), 38.4% (95% CI 26.9-49.7%), and 
20.7% (95% CI 17.1-24.5%) for der(1;7), -7/del(7q), and normal karyotype groups, 
respectively (Figure 1B). The univariate analysis using Gray test showed that the CIR 
was significantly higher for -7/del(7q) group than for normal karyotype group (P<.001), 
whereas no significant difference was noted between der(1;7) and normal karyotype 
groups (P=.816). Furthermore, -7/del(7q) group was likely to show a higher CIR than 
der(1;7) group in the Kaplan-Meier analysis (P=.015). The multivariate analysis 
demonstrated that CIR was significantly higher in -7/del(7q) group than in normal 
karyotype group (HR 2.11, 95% CI 1.36-3.280, P=.001) (see Table 2). There was no 
interaction modification between the cytogenetic group and other covariates. In the 
univariate and multivariate analyses, three factors were significant: PS at transplantation 
(PS 1-4, HR 2.32, 95% CI 1.38-3.90, P=.002), the use of anti-thymocyte globulin (ATG) 
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during conditioning (presence, HR 2.42, 95% CI 1.29-4.57, P=.006), and the type of 
donor source (unrelated bone marrow, HR 0.57, 95% CI 0.34-0.94, P=.028; unrelated 
cord blood, HR 1.58, 95% CI 1.01-2.51, P=.047) (see Supplemental Table 2). For the 
comparison between -7/del(7q) and der(1;7) groups, the higher CIR among -7/del(7q) 
group was maintained in the multivariate analysis (HR 2.19, 95% CI 1.08-4.44, P=0.029) 
(supplemental Table 3). 
The 3-year TRM were 31.1% (95% CI 20.0-42.7%), 27.1% (95% CI 17.0-38.1%), and 
29.1% (95% CI 25.0-33.3%) in the der(1;7), -7/del(7q), and normal karyotype groups, 
respectively (Figure 1C). The univariate and multivariate analyses did not identify the 
cytogenetic group as a significant factor for TRM. However, in the multivariate analysis, 
four factors correlated with higher TRM: recipient age at transplantation (≥60 year, HR 
1.46, 95% CI 1.00-2.11, P=.045), the type of donor source (unrelated bone marrow, HR 
1.72, 95% CI 1.11-2.66, P=.016; HLA-mismatched related graft, HR 3.02, 95% CI 1.73-
5.24, P<.001; unrelated cord blood, HR 2.25, 95% CI 1.35-3.74, P=.002), the interval 
from diagnosis to transplantation (>7.8 months, HR 1.68, 95% CI 1.24-2.29, P=.001), and 
the year of transplantation (2004-2008, HR 0.62, 95% CI 0.41-0.94, P=.024; 2009-2012, 
HR 0.57, 95% CI 0.38-0.89, P=.013). The causes of death were shown in supplemental 
Table 4. No significant difference was observed among 3 groups. 
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OS by the cytogenetic group in patients with early disease status 
Among patients with early disease status at transplantation, 23, 29, and 347 showed 
der(1;7), -7/del(7q), and normal karyotype, respectively (Supplemental Table 5). 
 The 3-year probabilities of OS after allo-HSCT were 47.3% (95% CI 21.5-69.5%), 
70.5% (95% CI 49.3-84.1%), and 70.9% (95% CI 65.6-75.5%) in der(1;7), -7/del(7q), 
and normal karyotype groups, respectively (Figure 2A). The univariate and multivariate 
analyses revealed no significant differences in OS among three groups (Table 3). There 
was no interaction modification between the cytogenetic group and other covariates. In 
the multivariate analysis, recipient age at transplantation (≥60 years, HR 2.21, 95% CI 
1.42-3.44, P<.001), the type of donor source (unrelated cord blood, HR 1.77, 95% CI 
1.03-3.04, P=.037), and the type of disease-altering therapy prior to allo-HSCT (intensive 
chemotherapy, HR 2.10, 95% CI 1.15-3.84, P=.016) correlated with shorter OS 
(Supplemental Table 6). 
 
Relapse and TRM by the cytogenetic group in patients with early disease status 
 The 3-year CIR were 9.5% (95% CI 1.5-26.8%), 13.8% (95% CI 4.2-29.0%), and 5.6% 
(95% CI 3.5-8.4%) in der(1;7), -7/del(7q), and normal karyotype groups, respectively 
17 
(Figure 2B). In terms of the cytogenetic group, the univariate and multivariate analyses 
showed no significant differences in CIR among three groups (see Table 3). Four factors 
other than the cytogenetic group correlated with a higher CIR: recipient age at 
transplantation (50-59 years, HR 3.08, 95% CI 1.05-9.10, P=.041), the intensity of the 
conditioning regimen (non-myeloablative conditioning regimen, HR 11.01, 95% CI 2.55-
47.54, P=.001), the type of donor source (unrelated bone marrow, HR 0.28, 95% CI 0.10-
0.77, P=.014), and the period of transplantation (2004-2008, HR 0.19, 95% CI 0.41-0.87, 
P=.033) (see Supplemental Table 4). 
 The 3-year TRM were 42.8% (95% CI 17.0-66.7%), 18.3% (95% CI 7.7-32.7%), and 
23.3% (95% CI 18.8-28.0%) in der(1;7), -7/del(7q), and normal karyotype groups, 
respectively, without a significant difference (Figure 2C). The multivariate analysis 
demonstrated that the type of donor source (HLA-mismatched related graft, HR 2.44, 
95% CI 1.01-5.88, P=.047; unrelated cord blood, HR 2.55, 95% CI 1.34-4.83, P=.004) 
and type of disease-altering therapy prior to allo-HSCT (intensive chemotherapy, HR 2.05, 
95% CI 1.13-3.71, P=.018) had a significantly negative impact on TRM. There was no 




The primary objective of this retrospective study was to evaluate the prognostic impact 
of the loss of chromosome 7q on the post-transplant outcomes of MDS patients. Previous 
studies analyzed the prognostic impact of the loss of 7q regardless of additional 
cytogenetic abnormalities [12-14]. To the best of our knowledge, the present study 
examined the largest number of post-transplant patients with der(1;7) or -7/del(7q) as the 
sole cytogenetic abnormality. Namely, the cohort of this study enabled a better estimation 
of the true prognostic impact of der(1;7) and -7/del(7q) on post-transplant outcomes. 
The ratios of der(1;7) (n=94, 8.9%) and -7/del(7q) groups (n=104, 9.8%) to normal 
karyotype group (n=858, 81.3%) in our cohort were higher than those in the previous 
studies [28, 29]. Physician and patient willingness to consider the indication of allo-HSCT 
for these cytogenetic groups was reflected, at least in a part, the different distribution in 
our study. Another explanation for the different distribution was that der(1;7) was more 
frequent in Japanese than Caucasians as previously reported [29]. 
One of the main questions in the present study was the prognostic impact of der(1;7) 
after allo-HSCT. In the original IPSS [2], the loss of 7q was assigned as a poor prognosis 
factor, and der(1;7) was considered to be a more unfavorable indicator than normal 
karyotype. This resulted in the selection of aggressive therapeutic strategies for 
der(1;7)(q10;p10) group, including disease-altering treatments (i.e. DNA 
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hypomethylating agents, intensive chemotherapy, and allo-HSCT) [13]. However, it 
currently remains unclear whether der(1;7) exhibits a survival disadvantage over normal 
karyotype due to the lack of any direct comparisons between der(1;7) and normal 
karyotype in MDS patients. It is important to note that we did not observe any differences 
in post-transplant outcomes between der(1;7) and normal karyotype groups with early 
and advanced disease status. One possible interpretation of these results is that der(1;7) 
did not have a prognostic impact in MDS patients after allo-HSCT. 
 Another interesting result of the present study was that der(1;7) group showed a lower 
CIR than -7/del(7q) group among the patients with advanced disease status, suggesting 
that der(1;7) group would benefit from allo-HSCT more than -7/del(7q) groups. The 
recent studies revealed that MDS patients with der(1;7) had the distinct clinical and 
pathological features, including ethnical differences and mutation profile [29, 30]. 
However, it is controversial whether der(1;7) abnormality defines a separate prognostic 
group in the previous studies involved both transplant and non-transplant patients [12, 13, 
31]. In terms of prognostic value of der(1;7) group, our findings provided the clearer 
insights into clinical outcomes in MDS patients with der(1;7) who undergo allo-HSCT. 
The important result was that the impact of -7/del(7q) differed by disease status; it 
correlated with worse OS and higher CIR with advanced disease status, but not early 
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disease status. In other words, -7/del(7q) exhibited different influences on post-transplant 
outcomes by the trajectory of the bone marrow blast percentage from the initial diagnosis 
to the time of transplantation. Since MDS patients with -7/del(7q) were more likely to 
progress to advanced disease status [12], a bridging strategy using DNA hypomethylating 
agents and/or chemotherapy prior to allo-HSCT is warranted for these patients [32-34]. 
In this regard, the detection of somatic mutations related to disease progression may be 
useful for making better decisions on how to treat the -7/del(7q) group [35]. 
 Among patients with advanced disease status, CIR was significantly higher in -7/del(7q) 
group than in normal karyotype group. This may have been partly due to the larger burden 
of residual tumor cells after allo-HSCT in -7/del(7q) group than in normal karyotype 
group. Thus, the monitoring of minimal residual disease may be helpful for -7/del(7q) 
using novel molecular-based approaches (e.g. a digital polymerase chain reaction [PCR] 
method and next-generation sequencing), multiparameter flow cytometry, and WT1 
expression levels with PCR [36-38]. These approaches may help to employ and optimize 
post-transplant therapy, such as the introduction of DNA hypomethylating agents, other 
compounds, and donor lymphocyte infusion as pre-emptive strategies to prevent the 
future relapse of MDS [39-45]. 
It was interesting to note that conditioning regimen-related factors correlated with 
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increased CIR. The use of ATG in the conditioning regime for patients with advanced 
disease status and non-myeloablative conditioning regimen for those with early disease 
status were significant factors for a significantly higher CIR and were independent from 
the cytogenetic group. Previous studies indicated that the graft-versus-leukemia effect 
and optimal intensity of the conditioning regimen were crucial for the long-term survival 
of MDS patients [24, 46-50]. These findings suggested that careful attention to the 
conditioning regimen in consideration of the disease status at transplantation is needed 
for patients with single der(1;7) or -7/del(7q) abnormality and normal karyotype. 
We were unable to assess the impact of somatic mutations due to the lack of data in 
TRUMP. Previous studies showed that the distinct mutation spectrum was identified in 
each karyotype; MDS patients with der(1;7) more often had RUNX1 gene mutations [12, 
30], whereas those with -7/del(7q) did the mutations in SAMD9, SAMD9L, EZH2, MLL3, 
and TP53 genes [51, 52]. Based on the presence of mutations in several genes, such as 
RUNX1 and TP53 genes, negatively affecting post-transplant outcomes [53, 54], further 
attempts to integrate cytogenetics, molecular genetics, and pathological data are crucial 
to generate better prognostic system for pre-transplant candidates with the loss of 
chromosome 7q. In addition, the sequencing-based monitoring for measurable residual 
disease was reported to be helpful for predicting disease progression following allo-HSCT 
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[55], which could support the decision to promptly initiate preemptive and salvage 
treatment. For MDS patients with der(1;7) or -7/del(7q) abnormality, it would be crucial 
to develop the optimal diagnostic modality using cytogenetic analysis in combination 
with sequencing-based monitoring, on the basis sensitivity and accessibility. 
There were several limitations in the present study. We were unable to evaluate the 
impact of IPSS, revised IPSS, and karyotype, including additional cytogenetic 
abnormalities, before allo-HSCT on post-transplant outcome [56-58]. Considering these 
predictive values for post-transplant outcomes, it would be of interest to determine 
whether these factors are helpful for risk-stratification among der(1;7) or -7/del(7q) 
groups. Furthermore, we carefully assessed the eligibility of patients who met all 
inclusion and exclusion criteria; however, patient characteristics and transplant 
procedures were heterogeneous. These factors may have exerted a bias and potentially 
affected the results obtained. Therefore, these results need to be cautiously interpreted 
and confirmed in larger prospective studies. 
 In conclusion, the present study showed that allo-HSCT may provide durable remission 
for MDS patients with the loss of chromosome 7q, whereas its impact on OS and CIR 
after transplantation may differ based on the type of loss of 7q. The present results may 
contribute to improving the management of MDS patients with the loss of chromosome 
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Figure 1. Post-transplant outcomes of MDS with advanced disease status 
(A) Overall survival (OS) after allo-HSCT. (B) Cumulative incidence of relapse (CIR). 
(C) Cumulative incidence of transplant-related mortality (TRM). 
 
Figure 2. Post-transplant outcomes of MDS with early disease status 
(A) OS. (B) CIR. (C) TRM. 
  
39 
Table 1. Patient characteristics 
 Advanced disease status Early disease status P 
Total 655 399  
Median age at allo-HSCT (range), y 51 (16 - 73) 44 (16 - 72) <.001
Age at allo-HSCT <.001
    ≤ 49 251 243  
    50-59 214 93  
    ≥ 60 190 63  
Gender  .025 
    Male 433 236  
    Female 222 163  
Sex match  
    match 349 203  
    mismatch 282 188  
    missing 24 8  
Karyotype .001 
    der(1;7) 69 23  
    -7/del(7q) 75 29  
    Normal karyotype 511 347  
FAB at diagnosis <.001
    RA 84 386  
    RARS 5 13  
    RAEB 434 -  
    RAEB-t 132 -  
IPSS at diagnosis  
    Low 29 33  
    Intermediate-1 136 170  
    Intermediate-2 197 21  
    High 78 1  
    Missing 215 174  
Performance status at allo-HSCT  
    0 306 175  
    1-4 297 202  
    Missing 52 22  
Bone marrow blasts at allo-HSCT <.001
    <5% 85 299  
    ≥5% 570 -  
Conditioning regimen intensity .932 
    Myeloablative 392 243  
    Reduced intensity 231 138  
    Non-myeloablative 32 18  
Donor source <.001
    HLA-matched related 163 123  
    HLA-mismatched related 40 20  
    Unrelated bone marrow 284 198  
    Unrelated cord blood 168 58  
GVHD prophylaxis  
    CsA-based 300 181  
    Tac-based 345 212  
    Other than calcineurin inhibitor-based 7 6  
    Missing 3 0  
Antithymocyte globulin .085 
    No 608 358  
    Yes 47 41  
Year of allo-HSCT .008 
    1999-2003 131 92  
    2004-2008 194 145  
    2009-2012 330 162  
Interval between diagnosis and allo-HSCT, mo 17.5 (0.5 - 394.6) <.001
Disease-altering therapy prior to allo-HSCT <.001
  Intensive chemotherapy alone 253 20  
  Azacitidine treatment alone 38 7  
  Intensive chemotherapy and azacitidine treatment 11 3  
  No treatment with disease-altering therapy 353 369  
Follow-up of survivors, y 3.1 (0.1 - 14.4) 4.3 (0.1 - 13.3)  
Final status  
    Alive 333 275  
    Death after relapse (disease-associated death) 134 26  
    Death without relapse (transplant-related death) 188 98  
Abbreviations: der(1;7) indicates, 46, XY (or 46, XX), +1, der(1;7)(q10;p10); -7/del(7q), monosomy 7 or the partial deletion 
of 7q; FAB classification, French-American-British classification; RA, refractory anemia; RARS, RA with ringed 
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sideroblasts; RAEB, RA with excess blasts; RAEB-t, RAEB in transformation; allo-HSCT, allogeneic hematopoietic stem 
cell transplantation; HLA, human leukocyte antigen; CsA, cyclosporine A; Tac, tacrolimus. 
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Table 2. Impact of the cytogenetic group in patients with advanced disease status 
  Univariate analysis Multivariate analysis 
Outcomes 
HR (95% CI) P HR (95% CI) P 
 Cytogenetic group 
 Overall mortality*  
   Normal karyotype 1.00 1.00 
 der(1;7) 1.05 (0.73-1.52) 0.781 0.90 (0.62-1.31) 0.583
 -7/del(7q) 1.49 (1.09-2.04) 0.012 1.38 (1.00-1.89) 0.048
 Transplant-related mortality†  
   Normal karyotype 1.00 - -
 der(1;7) 1.08 (0.69-1.70) 0.736 - -
 -7/del(7q) 0.95 (0.60-1.51) 0.840 - -
 Relapse‡  
   Normal karyotype 1.00 1.00 
 der(1;7) 0.93 (0.51-1.70) 0.808 0.90 (0.47-1.72) 0.757
 -7/del(7q) 2.15 (1.39-3.30) 0.001 2.11 (1.36-3.28) 0.001
The multivariate analysis including the cytogenetic group as a covariate identified other significant factors as follows: 
*Other factors associated with worse OS were recipient age at transplantation (≥60 year), performance status (PS) at 
transplantation (PS 1-4 and missing data), the type of donor source (unrelated cord blood), and the interval from diagnosis to 
transplantation (>7.8 months). 
†Other factors associated with worse TRM were recipient age at transplantation (≥60 year), the type of donor source (HLA-
mismatched related graft, unrelated bone marrow, and unrelated cord blood), and the interval from diagnosis to transplantation 
(>7.8 months); another factor associated with better TRM was the period of transplantation (2004-2008 and 2009-2012). 
‡Other factors associated with an increased relapse rate were PS at transplantation (PS 1-4), the use of ATG in the conditioning 
regimen (presence), the type of GVHD prophylaxis (other than calcineurin inhibitor-based), and type of donor source 
(unrelated cord blood); another factor associated with a reduced relapse rate was the type of donor source (unrelated bone 
marrow). 




Table 3. Impact of the cytogenetic group in patients with early disease status 
  Univariate analysis 
Outcomes 
HR (95% CI) P 
 Cytogenetic group 
 Overall mortality* 
   Normal karyotype 1.00
 der(1;7) 1.44 (0.73-2.85) 0.294
 -7/del(7q) 0.99 (0.50-1.95) 0.968
 Transplant-related mortality† 
   Normal karyotype 1.00
 der(1;7) 1.35 (0.65-2.79) 0.421
 -7/del(7q) 0.81 (0.36-1.86) 0.624
 Relapse‡ 
   Normal karyotype 1.00
 der(1;7) 1.56 (0.38-6.49) 0.537
 -7/del(7q) 2.47 (0.87-7.02) 0.091
The multivariate analysis including the cytogenetic group as a covariate identified other significant factors as follows: 
*Other factors associated with worse OS were recipient age at transplantation (≥60 year), the type of donor source (unrelated 
cord blood), and the type of disease-altering therapy prior to allo-HSCT (intensive chemotherapy alone). 
†Other factors associated with worse TRM were the type of donor source (HLA-mismatched related graft and unrelated cord 
blood) and type of disease-altering therapy prior to allo-HSCT (intensive chemotherapy alone). 
‡Other factors associated with an increased relapse rate were recipient age at transplantation (50-59 years) and the intensity 
of the conditioning regimen (non-myeloablative conditioning regimen); other factors associated with a reduced relapse rate 














Supplemental Table 1. Characteristics of patients with advanced disease status 
 Total 
 der(1;7) -7/del(7q) Normal P 
Total 69 75 511  
Median age at allo-HSCT (range), y 58 (19-73) 53 (16-73) 54 (16-73) 0.005 
Age at allo-HSCT    0.019 
    ≤ 49 15 33 203  
    50-59 24 22 168  
    ≥ 60 30 20 140  
Gender     0.002 
    Male 58 53 322  
    Female 11 22 189  
Sex match    0.358 
    match 39 33 277  
    mismatch 28 37 217  
    missing 2 5 17  
FAB at diagnosis    0.074 
    RA 16 7 61  
    RARS 0 1 4  
    RAEB 43 56 335  
    RAEB-t 10 11 111  
IPSS at diagnosis    <0.001 
    Low 2 1 26  
    Int-1 11 5 120  
    Int-2 30 25 142  
    High 15 19 44  
    Missing 11 25 179  
Performance status at allo-HSCT   0.143 
    0 32 25 249  
    1-4 33 43 221  
    Missing 4 7 41  
Bone marrow blasts at allo-HSCT    <0.001 
    <5% 3 2 80  
    ≥5% 66 73 431  
Intensity of the conditioning regimen    0.256 
    Myeloablative 35 40 317  
    Reduced intensity 30 32 169  
    Non-myeloablative 4 3 25  
Donor source    0.621 
    HLA-matched related 17 15 131  
    HLA-mismatched related 6 7 27  
    Unrelated bone marrow 26 33 225  
    Unrelated cord blood 20 20 128  
GVHD prophylaxis    0.625 
    CsA-based 34 38 228  
    Tac-based 33 35 277  
    Other 1 1 5  
    Missing 1 1 1  
Use of ATG in the conditioning regimen    0.601 
    No 66 70 472  
    Yes 3 5 39  
Year of allo-HSCT   0.224 
    1999-2003 8 15 108  
    2004-2008 18 25 151  
    2009-2012 43 35 252  
Interval between diagnosis and allo-HSCT, mo 9.4 (1.1-82.2) 7.3 (1.6-75.9) 7.8 (0.7-237.8) 0.402 
Disease-altering therapy prior to allo-HSCT    0.154 
  ICT alone 22 23 208  
  Azacitidine treatment alone 1 5 32  
  ICT and azacitidine treatment 2 1 8  
  No treatment with disease-altering therapy 44 46 263  
Follow-up of survivors, y 2.6 (0.3-11.8) 2.8 (0.3-11.1) 3.2 (0.1-14.4) 0.830 
Final status     
    Alive 36 28 269  
46 
    Death after relapse (disease-associated death) 12 26 96  
    Death without relapse (treatment-related death) 21 21 146  
47 
Abbreviations: der(1;7) indicates, 46, XY (or 46, XX), +1, der(1;7)(q10;p10); -7/del(7q), monosomy 7 or the partial deletion 
of 7q; FAB classification, French-American-British classification; RA, refractory anemia; RARS, RA with ringed 
sideroblasts; RAEB, RA with excess blasts; RAEB-t, RAEB in transformation; allo-HSCT, allogeneic hematopoietic stem 
cell transplantation; HLA, human leukocyte antigen; CsA, cyclosporine A; Tac, tacrolimus; ICT, intensive chemotherapy. 
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Supplemental Table 2. Prognostic factors analyzed in patients with advanced disease status 
 Overall mortality Treatment-related mortality Relapse
 Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
Variable HR  (95% CI) P  
HR 
(95% CI) P  
HR 
(95% CI) P  
HR 
(95% CI) P  
HR 
(95% CI) P  
HR  
(95% CI) P 
Patient sex      
  Female 1.00   1.00   1.00   - -  1.00   - - 
Male 1.40 (1.11-1.78) 0.005  
1.26
(0.98-1.61) 0.068  
1.30
(0.95-1.77) 0.102  - -  
1.19
(0.83-1.71) 0.341  - - 
Sex matching    
  Match 1.00   - -  1.00   - -  1.00   - - 
Mismatch 0.92 (0.73-1.15) 0.465  - -  
1.05
(0.78-1.41) 0.732  - -  
0.76
(0.53-1.08) 0.127  - - 
Age at transplantation      
  49 years or younger 1.00   1.00   1.00   1.00   1.00   not selected 
50-59 years 1.25 (0.95-1.63) 0.106  
1.15
(0.88-1.51) 0.315  
1.04
(0.73-1.48) 0.827  
0.98
(0.70-1.42) 0.981  
1.49
(0.99-2.23) 0.054  not selected 
Older than 59 years 1.74 (1.33-2.28) <0.001  
1.39
(1.05-1.85) 0.023  
1.43
(1.01-2.03) 0.042  
1.46
(1.00-2.11) 0.045  
1.46
(0.96-2.23) 0.077  not selected 
Performance status at allo-HSCT    
  0 1.00   1.00   1.00   1.00   1.00   1.00  
1-4 1.64 (1.29-2.07) <0.001  
1.56
(1.22-1.99) <0.001  
1.35
(0.99-1.83) 0.057  
1.33
(0.97-1.82) 0.073  
3.20
(1.96-5.23) <0.001  
2.51 
(1.52-4.13) <0.001 
Missing 1.88 (1.29-2.73) 0.001  
1.87
(1.26-2.77) 0.002  
2.11
(1.32-3.35) 0.002  
1.55
(0.90-2.68) 0.108  
0.67
(0.32-1.42) 0.297  
0.65 
(0.30-1.38) 0.259 
Blasts in bone marrow at allo-HSCT      
  Lower than 5%    1.00   - -  - -  - -  - - 
5% or higher 1.83 (1.25-2.67) 0.002  
1.40
(0.94-2.10) 0.099  
1.47
(0.91-2.36) 0.112  - -  
1.58
(0.91-2.75) 0.107  - - 
Conditioning regimen    
  MAC 1.00   not selected  1.00   - -  1.00   not selected 
RIC  1.31 (1.04-1.65) 0.023  not selected  
1.03
(0.76-1.39) 0.850  - -  
1.64
(1.16-2.33) 0.005  not selected 
NMAC 1.73 (1.12-2.68) 0.013  not selected  
0.80
(0.40-1.63) 0.543  - -  
2.77
(1.44-5.32) 0.002  not selected 
GVHD prophylaxis      
  Cyclosporine-based 1.00   - -  1.00   - -  1.00   1.00  
Tacrolimus-based 1.09 (0.87-1.36) 0.458  - -  
1.11
(0.83-1.48) 0.476  - -  
0.96
(0.68-1.34) 0.796  
1.00 
(0.67-1.49) 0.982 
Other 1.17 (0.43-3.17) 0.753  - -  not calculated  - -  
3.39
(1.26-9.09) 0.015  
4.50 
(1.81-11.19) 0.001 
Type of donor    
  HLA-matched related donor 1.00   1.00   1.00   1.00   1.00   1.00  
HLA-mismatched related donor 1.76 (1.11-2.81) 0.017  
1.55
(0.96-2.51) 0.074  
2.70
(1.53-4.76) 0.001  
3.02
(1.73-5.24) <0.001  
0.64
(0.27-1.50) 0.305  
0.41 
(0.16-1.04) 0.062 
Unrelated bone marrow donor 1.26 (0.94-1.70) 0.120  
0.95
(0.69-1.30) 0.752  
1.96
(1.31-2.92) 0.001  
1.72
(1.11-2.66) 0.016  
0.59
(0.37-0.92) 0.020  
0.57 
(0.34-0.94) 0.028 
Unrelated cord blood donor 2.35 (1.72-3.19) <0.001  
1.85
(1.33-2.56) <0.001  
2.24
(1.45-3.47) <0.001  
2.25
(1.35-3.74) 0.002  
1.64
(1.08-2.49) 0.020  
1.58 
(1.01-2.51) 0.047 
Period of transplantation      
  1999-2003 1.00   - -  1.00   1.00   1.00   not selected 
2004-2008 0.91 (0.68-1.22) 0.529  - -  
0.71
(0.49-1.04) 0.075  
0.62
(0.41-0.94) 0.024  
1.58
(0.96-2.58) 0.072  not selected 
2009-2012 0.79 (0.60-1.05) 0.105  - -  
0.69
(0.49-0.97) 0.031  
0.57
(0.38-0.89) 0.013  
1.24
(0.77-2.01) 0.379  not selected 
Interval from diagnosis to allo-HSCT*    
  7.8 months or shorter 1.00   - -  1.00   1.00 -  1.00   - - 
Longer than 7.8 months  1.50 (1.20-1.87) <0.001  
1.54
(1.22-1.95) <0.001  
1.79
(1.33-2.41) <0.001  
1.68
(1.24-2.29) 0.001  
0.90
(0.64-1.27) 0.556  - - 
Use of ATG in the conditioning regimen     
  No 1.00   not selected  1.00   - -  1.00   - - 
  Yes  1.46 (0.99-2.16) 0.054  not selected  
0.85
(0.45-1.59) 0.612  - -  
1.85
(1.08-3.14) 0.024  
2.42 
(1.29-4.57) 0.006 
Disease-altering therapy prior to allo-HSCT                  
  No treatment with disease-altering therapy 1.00   - -  1.00   - -  1.00   - - 
  ICT alone 
1.05 
(0.83 - 1.31) 0.690  - -  
0.97
(0.72 - 1.30) 0.819  - -  
1.11
(0.79 - 1.57) 0.555  - - 
  Azacitidine treatment alone 
0.75 
(0.40 - 1.38) 0.348  - -  
0.72
(0.34 - 1.54) 0.401  - -  
0.84
(0.37 - 1.93) 0.681  - - 
  ICT and azacitidine treatment 
1.87 
(0.83 - 4.24) 0.133  - -  
2.15
(0.92 - 5.04) 0.077  - -  
0.45
(0.59 - 3.49) 0.447  - - 
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*The median interval from the diagnosis to allo-HSCT was 7.8 months in MDS patients with advanced disease status. 
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Supplemental Table 3. Prognostic factors analyzed in patients having der(1;7) or -7/del(7q) with advanced disease status  
  Overall survival Treatment-related mortality Relapse
 Univariate analysis Multivariate analysis Univariate analysis  Multivariate analysis Univariate analysis Multivariate analysis 
Variable HR  (95% CI) P  
HR 
(95% CI) P 
HR 
(95% CI) P  
HR 
(95% CI) P 
HR 
(95% CI) P  
HR 
(95% CI) P 
Karyotype at diagnosis        
   der(1;7) 1.00    - - 1.00    - - 1.00    1.00   
 -7/del(7q) 1.42 (0.91-2.22) 0.120  - - 
0.88
(0.48-1.61) 0.682  - - 
2.28
(1.15-4.51) 0.018  
2.19
(1.08-4.44) 0.029 
Patient sex     
   Female 1.00  - - 1.00   - - 1.00  1.00  
 Male 1.51 (0.87-2.62) 0.139 - - 
0.77





Sex matching        
  Match 1.00    - - 1.00    - - 1.00    - - 
Mismatch 0.98 (0.62-1.55) 0.938  - - 
0.73
(0.39-1.37) 0.327  - - 
1.11
(0.57-2.14) 0.766  - - 
Age at transplantation     
  49 years or younger 1.00  - - 1.00   - - 1.00  not selected 
50-59 years 1.24 (0.72-2.16) 0.439 - - 
0.94
(0.47-1.89) 0.866  - - 
1.91
(0.76-4.80) 0.166 not selected 
Older than 59 years 1.32 (0.77-2.27) 0.315 - - 
0.61
(0.28-1.32) 0.214  - - 
2.96
(1.24-7.07) 0.015 not selected 
Performance status at allo-HSCT        
  0 1.00    not selected 1.00    1.00   1.00    1.00   
1-4 1.87 (1.03-3.42) 0.041  not selected 
0.33




(1.88-8.24) <0.001  
2.93
(1.35-6.35) 0.007 
Missing 1.56 (0.71-3.42) 0.270  not selected 
2.35
(0.86-6.44) 0.095  
2.41
(0.89-6.57) 0.084 not calculated  not calculated 
Blast in bone marrow at allo-HSCT     
  Lower than 5% 1.00  - - 1.00   - - 1.00  - - 
5% or higher 1.86 (0.46-7.57) 0.387 - - 
1.66
(0.24-11.40) 0.604  - - 
0.78
(0.23-2.62) 0.685 - - 
Conditioning regimen        
  MAC 1.00    - - 1.00    - - 1.00    - - 
RIC  1.03 (0.66-1.63) 0.882  - - 
0.85
(0.46-1.58) 0.613  - - 
1.31
(0.70-2.45) 0.406  - - 
NMAC 1.14 (0.41-3.19) 0.802  - - 
0.89
(0.21-3.73) 0.876  - - 
0.64
(0.07-5.71) 0.691  - - 
GVHD prophylaxis     
  Cyclosporine-based 1.00  - - 1.00   - - 1.00  - - 
Tacrolimus-based 1.00 (0.64-1.57) 0.998 - - 
0.87










Type of donor        
  HLA-matched related donor 1.00    1.00   1.00    not selected 1.00    1.00   




(0.97-9.09) 0.056  not selected 
0.63
(0.13-3.02) 0.562  
0.59
(0.12-2.86) 0.509 




(1.10-7.13) 0.031  not selected 
0.61
(0.23-1.62) 0.324  
0.73
(0.24-2.16) 0.564 




(0.74-5.68) 0.166  not selected 
2.83
(1.20-6.67) 0.018  
2.76
(1.06-7.20) 0.037 
Period of transplantation     
  1999-2003 1.00  -  1.00   not selected 1.00  - - 
2004-2008 0.83 (0.46-1.51) 0.541 -  
0.49
(0.22-1.07) 0.075  not selected 
2.40
(0.67-8.60) 0.178 - - 
2009-2012 0.62 (0.35-1.11) 0.35 -  
0.47
(0.23-0.95) 0.035  not selected 
2.14
(0.62-7.40) 0.230 - - 
Interval from diagnosis to allo-HSCT      
  7.8 months or shorter 1.00    -   1.00    1.00   1.00    1.00   
Longer than 7.8 months  1.28 (0.82-2.00) 0.268  -   
2.32




(0.29-1.06) 0.073  
0.53
(0.25-1.10) 0.250 
Aanti-thymocyte globuline as conditioning     
  No 1.00  1.00  1.00   1.00  1.00  - - 








(0.06-4.11) 0.530  - - 
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Supplemental Table 4. Causes of death among patients with advanced disease status 
  
  
No. of patients (%) 
der(1;7) -7/del(7q) Normal 
Recurrence of MDS 12 (35.3) 26 (55.3) 96 (39.8) 
Graft failure/rejection 0 (0.0) 0 (0.0) 6 (2.5) 
GVHD 3 (8.8) 7 (14.9) 21 (8.7) 
Infection 7 (20.6) 7 (14.9) 44 (18.3) 
Idiopathic pneumonia 2 (5.9) 2 (4.3) 13 (5.4) 
Organ failure 3 (8.8) 3 (6.4) 26 (10.8) 
Secondary cancer 0 (0.0) 0 (0.0) 3 (1.2) 
Bleeding 1 (2.9) 1 (2.1) 12 (5.0) 
TMA 0 (0.0) 0 (0.0) 4 (1.7) 
SOS 1 (2.9) 0 (0.0) 8 (3.3) 
Other 5 (14.7) 1 (2.1) 8 (3.3) 
Total 34 (100.0) 47 (100.0) 241 (100.0) 





Supplemental Table 5. Characteristics of patients with early disease status 
 Total 
 der(1;7) -7/del(7q) Normal P 
Total 23 29 347  
Median age at allo-HSCT (range), y 48 (18-66) 51 (16-69) 43 (16-72) 0.045 
Age at allo-HSCT    0.234 
    <49 12 13 218  
    50-59 8 10 75  
    ≥60 3 6 54  
Gender     0.013 
    Male 20 19 197  
    Female 3 10 150  
Sex match    0.59 
    match 13 11 179  
    mismatch 10 17 161  
    missing 0 1 7  
FAB at diagnosis    0.663 
    RA 23 28 335  
    RARS 0 1 12  
    RAEB - - -  
    RAEB-t - - -  
IPSS at diagnosis    <0.001 
    Low 1 2 30  
    Int-1 5 0 165  
    Int-2 9 10 2  
    High 0 0 1  
    Missing 8 17 149  
Performance status at allo-HSCT    0.898 
    0 11 14 150  
    1-4 12 14 176  
    Missing 0 1 21  
Intensity of the conditioning regimen    0.334 
    Myeloablative 13 16 214  
    Reduced intensity 10 13 115  
    Non-myeloablative 0 0 18  
Donor source    0.254 
    HLA-matched related 7 14 102  
    HLA-mismatched related 1 2 17  
    Unrelated bone marrow 10 8 180  
    Unrelated cord blood 5 5 48  
GVHD prophylaxis    0.65 
    CsA-based 10 14 157  
    Tac-based 12 14 186  
    Other 1 1 4  
Use of ATG in the conditioning regimen    0.096 
    No 23 28 307  
    Yes 0 1 40  
Year of allo-SCT    0.159 
    1999-2003 1 8 83  
    2004-2008 12 12 121  
    2009-2012 10 9 143  
Interval between diagnosis and allo-HSCT, mo 10.1 (0.5-133.2) 18.9 (2.2-119.9) 19.7 (0.5-394.6) 0.019 
Disease-altering therapy prior to SCT    0.152 
  Intensive chemotherapy alone 1 1 18  
  Azacitidine treatment alone 1 2 4  
  Intensive chemotherapy and azacitidine treatment 0 1 2  
  No treatment with disease-altering therapy 21 25 323  
Follow-up of survivors, y 1.8 (0.3-9.6) 4.4 (0.5-10.2) 4.4 (0.1-13.3) 0.199 
Final status     
    Alive 14 20 241  
    Death after relapse (disease-associated death) 2 3 21  
    Death without relapse (treatment-related death) 7 6 85  
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Supplemental Table 6. Prognostic factors analyzed in patients with early disease status 
 Overall mortality Treatment-related mortality  Relapse







Variable HR  (95% CI) P  
HR  
(95% CI) P  
HR  
(95% CI) P 
HR  









Patient sex        













0.338 - - 
Sex matching        













0.356 - - 
Age at transplantation        



































Performance status at allo-HSCT        


























0.762 - - 
Conditioning regimen        



































GVHD prophylaxis        


























0.736 - -  not calculated not calculated 
Type of donor        
  HLA-matched related donor 1.00   1.00   1.00  1.00   1.00  1.00  








0.037 2.44 (1.01-5.88) 0.047  not calculated not calculated 


































Period of transplantation        



































Interval from diagnosis to allo-HSCT*       
  17.5 months or shorter 1.00   - -  1.00  - -  1.00  - - 












0.147 - - 
Use of ATG in the conditioning regimen      
  No 1.00   - -  1.00  - -  1.00  - - 












0.327 - - 
Disease-altering therapy prior to 
allo-HSCT 
               
  No treatment with disease-altering 
therapy 
1.00   1.00   1.00  1.00   1.00  not selected 












0.391 not selected 












0.011 not selected 
  ICT and azacitidine treatment not calculated  not calculated - not calculated not calculated - not calculated not selected 




Supplemental Table 7. Causes of death among patients with early disease status 
  
  
No. of patients (%) 
der(1;7) -7/del(7q) Normal 
Recurrence of MDS 3 (30.0) 2 (25.0) 21 (19.8) 
Graft failure/rejection 0 (0.0) 0 (0.0) 5 (4.7) 
GVHD 2 (20.0) 1 (12.5) 12 (11.3) 
Infection 3 (30.0) 2 (25.0) 28 (26.4) 
Idiopathic pneumonia 1 (10.0) 1 (12.5) 9 (8.5) 
Organ failure 1 (10.0) 1 (12.5) 13 (12.3) 
Secondary cancer 0 (0.0) 0 (0.0) 0 (0.0) 
Bleeding 0 (0.0) 0 (0.0) 7 (6.6) 
TMA 0 (0.0) 0 (0.0) 3 (0.0) 
SOS 0 (0.0) 0 (0.0) 3 (2.8) 
Other 0 (0.0) 1 (12.5) 5 (2.8) 





































(A) The 3-year probabilities of overall survival (OS) after allo-HSCT were 69.8% (95% confidential interval 
[CI] 64.8-74.3%) and 49.3% (95% CI 44.8-53.3%) in patients with early and advanced disease status, 
respectively (P<.001). (B) The 3-year cumulative incidence rates of relapse (CIR) were 6.4% (95% CI 4.3-
9.2%) and 22.6% (95% CI 19.3-26.1%) in patients with early and advanced disease status, respectively 
(P<.001). (C) The 3-year cumulative incidence rates of transplant-related mortality (TRM) were 24.1% (95% 
CI 19.8-28.6%) and 30.2% (95% CI 26.4-34.0%) in patients with early and advanced disease status, 
respectively (P=.071).  
